Cancer in People with HIV.

Autor: Odeny TA; Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid Ave., CB 8056, St. Louis, MO 63110-1093, USA., Fink V; Research Department, Fundación Huésped, Av. Forest 345 (C1427CEA) Buenos Aires, Argentina., Muchengeti M; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, South Africa., Gopal S; Center for Global Health, National Cancer Institute, 9609 Medical Center Drive, Rockville MD 20850, USA. Electronic address: satish.gopal@nih.gov.
Jazyk: angličtina
Zdroj: Infectious disease clinics of North America [Infect Dis Clin North Am] 2024 Sep; Vol. 38 (3), pp. 531-557.
DOI: 10.1016/j.idc.2024.06.007
Abstrakt: We review the intersection of human immunodeficiency virus (HIV) and cancer globally, including the complex interplay of oncogenic infections, chronic inflammation, and behavioral and other factors in increasing cancer risk among people with HIV (PWH). We discuss current cancer screening, prevention, and treatment recommendations for PWH. Specific interventions include vaccination, behavioral risk reduction, timely HIV diagnosis and treatment, screening for specific cancer sites, and multifaceted treatment considerations unique to PWH including supportive care and drug interactions. Finally, the potential of novel therapies and the need for inclusive cancer clinical trials are highlighted. Collaborative multidisciplinary efforts are critical for continued progress against cancer among PWH.
Competing Interests: Disclosure T.A. Odeny received grant funding from Gilead Sciences. V. Fink participated as speaker and expert discussant for MSD. The opinions expressed in this article are the authors own and do not reflect the view of the NIH, the Department of Health and Human Services, or the United States Government.
(Published by Elsevier Inc.)
Databáze: MEDLINE